Expanding HIV Prevention Options for Women

The IAS-ILF would particularly like to thank Mitchell Warren (AVAC), the experts and key informants that graciously provided their time and insight and Rodney Kort for leading the writing of this report. Acknowledgements Photo disclaimer: The photographs used in this publication are for illustrative purposes only; they do not imply HIV status, or any particular attitudes, behaviors, or actions on the part of any person who appears in the photographs. 3 Mitchell Warren opened the session by introducing his Co-Chair, Linda-Gail Bekker, welcoming participants, and noting the enormous data generated from a number of oral and topical tenofovir (respectively, TDF and TFV 1) or TDF/emtricitabine (FTC)-based HIV prevention trials in the past few years. The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial was the first study of TFV prophylaxis (in a 1% topical gel) to demonstrate efficacy. A number of other studies have since reported results and, given the variable findings, Warren underscored the need to carefully analyse the data and their implications for expanding HIV prevention options for women. He emphasized that, on balance, the results demonstrated that pre-exposure prophylaxis (PrEP) can be efficacious in preventing HIV infection, but that substantial qualitative, quantitative and post-hoc analyses are required to explore findings from these trials in order to develop a range of ARV-based prevention options tailored to maximize their use and protective benefit among women.